The Law Offices of Frank R. Cruz announces an investigation of Reata Pharmaceuticals, Inc. (“Reata” or the “Company”) (NASDAQ: RETA) on behalf of investors concerning the Company’s possible violations of federal securities laws.
If you are a shareholder who suffered a loss, click here to participate.
On December 6, 2021, the FDA released a briefing document regarding Reata’s chronic kidney disease drug candidate, bardoxolone methyl. Therein, the FDA stated that the data submitted by Reata did not “demonstrate that bardoxolone is effective in slowing the loss of kidney function in patients with [Alport syndrome].”
On this news, Reata’s share price fell $29.77, or 37.8%, to close at $48.92 per share on December 6, 2021, thereby injuring investors.
Follow us for updates on Twitter: twitter.com/FRC_LAW.
If you purchased Reata securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to firstname.lastname@example.org, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
The Law Offices of Frank R. Cruz Announces Investigation of Reata Pharmaceuticals, Inc. (RETA) on Behalf of Investors